Skip to main content

Table 5 Percent Change in Functional Measures in Pimobendan versus Placebo Groups

From: Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy

 

Post-pimobendan

Post-placebo

P value

LAFS 2-D4 [median % change (IQR)]

12.08 (6.25, 17.43)

−5.77 (− 19.75, 3.28)

0.03

Mitral TDI S5 (mean % change ± SD)

10.76 ± 19.85

−6.42 ± 23.07

0.11

LVOT Vmax5 (mean % change ± SD)

20.08 ± 28.92

20.39 ± 31.51

0.96

RVOT Vmax5 (mean % change ± SD)

22.6 ± 23.8

19.92 ± 10.25

0.68

HR at LVOT Vmax5 (mean % change ± SD)

4.67 ± 6.7

2.8 ± 12.8

0.72

HR at RVOT Vmax5 (mean bpm ± SD)

5.1 ± 12.9

6.26 ± 9.30

0.80

  1. 4Mann-Whitney U Test
  2. 5Welch’s T Test
  3. LAFS, left atrial fractional shortening; 2-D, 2-dimensional echocardiography; SD, standard deviation; TDI, tissue Doppler imaging; LVOT Vmax, left ventricular outflow tract maximal velocity, IQR interquartile range, RVOT Vmax, right ventricular outflow tract maximal velocity
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us